SCH 351591
Alternative Names: D 4396Latest Information Update: 03 Sep 2007
Price :
$50 *
At a glance
- Originator Celltech R&D
- Developer Celltech R&D; Schering-Plough
- Class Antiasthmatics; Antibronchitics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 03 Sep 2007 Discontinued - Phase-I for Asthma in United Kingdom (PO)
- 03 Sep 2007 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (PO)
- 20 Jan 2005 No development reported - Phase-I for Asthma in United Kingdom (PO)